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The purpose of this article is to provide a succinct summary of the different 
experimental approaches that have been used in preclinical postoperative 
cognitive dysfunction research, and an overview of the knowledge that has 
accrued. This is not intended to be a comprehensive review, but rather is 
intended to highlight how the many different approaches have contributed 
to our understanding of postoperative cognitive dysfunction, and to identify 
knowledge gaps to be filled by further research. The authors have organized 
this report by the level of experimental and systems complexity, starting with 
molecular and cellular approaches, then moving to intact invertebrates and 
vertebrate animal models. In addition, the authors’ goal is to improve the 
quality and consistency of postoperative cognitive dysfunction and periop-
erative neurocognitive disorder research by promoting optimal study design, 
enhanced transparency, and “best practices” in experimental design and 
reporting to increase the likelihood of corroborating results. Thus, the authors 
conclude with general guidelines for designing, conducting and reporting 
perioperative neurocognitive disorder rodent research.
(ANESTHESIOLOGY 2019; XXX:00–00)
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Patients over the age of about 65 yr are the largest con-sumers of procedural care.1 Impairments in cognitive 
ability are the most common complications experienced in 
the postoperative period by these older individuals.2,3 These 
impairments include postoperative delirium, occurring 
in the hours to days after surgery, as well as more durable 
deficits in executive function, memory, and other cognitive 
domains. The duration of cognitive impairment is variable, 
with most symptoms resolving in weeks to months, but 
in a minority the impairment continues or reemerges.4,5 
Previously, all forms of impairment were called postoper-
ative cognitive dysfunction, but more recently, a recom-
mended change to perioperative neurocognitive disorders 
has been made.6,7 This change better aligns these disorders 
with the phenotypically similar neurocognitive diagno-
ses listed in the Diagnostic and Statistical Manual of Mental 
Disorders, version 5, such as Alzheimer disease8–14 and 
Parkinson disease.15 Clinical studies have identified age, 
infection, and preexisting cognitive disorders as consis-
tent risk factors for perioperative neurocognitive disorder6; 
perioperative features, such as surgery duration, anesthetic 
management, and intraoperative physiology (e.g., hypoten-
sion, hypoxemia) have not been rigorously implicated. In 
fact, other than the most acute forms of dysfunction (e.g., 
postoperative delirium), the relationship of postoperative 
cognitive impairment with the surgery or anesthetic itself 
remains uncertain. Thus, despite consensus on the existence 
and character of perioperative neurocognitive disorder, 
whether anesthesia and surgery can be considered as etiol-
ogies, especially of the most persistent forms, has been the 
subject of controversy.16
Mechanistic interpretations of patient outcomes always 
suffer from the enormous complexity of patient care set-
tings and medical interventions, as well as the diverse 
genetic and environmental influences that patients bring to 
these settings. Because the ability to dissect all these fac-
tors in humans is limited, researchers have turned to var-
ious preclinical models to reveal underlying causation and 
mechanisms. In this approach, ideas flowing from patient 
observations and mechanisms flowing from the preclini-
cal observations can be tested and confirmed in models of 
appropriate complexity, with the long-range goal of opti-
mizing perioperative brain health.
The purpose of this review is to provide a succinct sum-
mary of the different approaches used in preclinical periop-
erative neurocognitive disorder research and to offer an 
overview of the knowledge that has accrued. This report 
is not intended to be a comprehensive review, but rather 
to highlight how the different approaches have contrib-
uted to our understanding of perioperative neurocognitive 
disorder, and to identify knowledge gaps that need to be 
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addressed by further research. Finally, our goal is to improve 
the quality of research in the field by promoting optimal 
study design, enhanced transparency and consistency, and 
advocacy for “best practices” in reporting to increase the 
likelihood of reproducing and translating results. We have 
organized this brief report by the level of experimental 
and systems complexity, starting with molecular and cel-
lular approaches, then moving to intact invertebrates and 
vertebrate animal models. In the end, we provide general 
guidelines for designing, conducting and reporting periop-
erative neurocognitive disorder rodent research. These sug-
gestions are not intended to be overly prescriptive or to 
stifle creativity, but rather to provide helpful guidelines that 
will enhance reproducibility and translatability.
In Vitro Models Used to Study perioperative 
Neurocognitive Disorder
Molecular
Experimental models that examine the consequences of 
exposure to an anesthetic drug at the molecular level offer 
several key advantages. This reductionist approach allows 
the number of variables to be limited, and directly manip-
ulated, and thus offers the advantage of testing mechanis-
tic hypotheses. On the other hand, molecular studies have 
the disadvantage of being limited in their ability to translate 
to behavioral correlates. Generally, the approach allows for 
high-throughput studies, where several factors such as key 
target receptors and components in cell signaling pathways 
can be explored. Variability between experiments can include 
biologic variation but generally reflects only technical varia-
tion. Examples here were the demonstration that some gen-
eral anesthetics accelerate the aggregation of the Alzheimer 
disease–associated amyloid β8,17 protein, through a defined 
biophysical mechanism.18 Given the phenotypic similarity 
between Alzheimer disease and some forms of perioperative 
neurocognitive disorder, these studies set the stage for dis-
cussion below on cell and animal studies (see Cell Culture 
Models and Animal Models of Postoperative Cognitive 
Dysfunction and Perioperative Neurocognitive Disorder 
sections), which has focused on amyloidopathy as a possi-
ble cause of cognitive impairment. The available molecular 
data at this level are relatively sparse. For example, we do not 
know if or how anesthetics interact with isolated tau, tau/
tubulin assemblies, synuclein, or TDP-43,19,20 all of which are 
neurodegenerative disease–associated proteins. Also, while 
considerable information exists on the interaction of anes-
thetics with certain integrins and other components of the 
innate immune response,21–24 it remains unclear if or how 
anesthetics interact with, for example, the many interleuk-
ins and damage-associated molecular patterns, small proteins, 
and their receptors that trigger or sustain an inflammatory 
response. It is important to note that this very reductionist 
approach eliminates important macromolecular interactions 
normally present in the cellular milieu, and cannot mimic 
anything resembling the complexity of surgery. However, key 
factors such as pH, oxygen levels, and temperature need to be 
considered when adopting these models.
Many membrane-associated proteins, especially ion 
channels, are both anesthetic targets and key participants in 
innate immune or cognitive responses21 and thus have been 
implicated in perioperative neurocognitive disorder by asso-
ciation. Thus, in situ molecular approaches have examined 
complex proteins such as transmitter- or voltage-gated ion 
channels, when isolated in their membrane environment 
using techniques such as electrophysiology and high-res-
olution microscopy. Such ion channels may include those 
expressed in neurons and glia, as well as circulating immune 
cells. Many, but not all, intermolecular interactions such 
as regulatory protein–protein interations are preserved in 
these studies. In general, the effects of anesthetics on the 
activity of ion channels, such as γ-aminobutyric acid type 
A (GABAA) receptors, N-methyl-d-aspartate receptors, 
hyperpolarization-activated cyclic nucleotide–gated chan-
nels, tandem-pore potassium channels, and transient recep-
tor potentials, among others, have been studied25; however, 
these studies have primarily focused on identifying poten-
tial targets that mediate the desired clinical properties of 
anesthetics rather than potential “neurotoxic” properties. 
However, molecular actions do not always translate to the 
expected desired or undesired behavioral effects, especially 
when multiple such actions exist concurrently. For exam-
ple, the neuronal inositol 1,4,5 trisphosphate receptor and 
the ryanodine receptors are calcium-release channels in the 
endoplasmic reticulum that are activated by most of the vol-
atile anesthetics. The resultant elevation in intracellular cal-
cium could contribute to the hypnotic effects of the drugs 
depending on placement within a neuronal circuit; however, 
the increase in calcium could also trigger mitochondriopa-
thy, apoptosis, and other forms of cell death. In fact, dantro-
lene, a ryanodine receptor inhibitor, is being investigated as 
a therapy for neurodegeneration,26,27 but has not yet been 
explored in intact animal models of postoperative cognitive 
dysfunction and perioperative neurocognitive disorder. If 
therapeutic, dantrolene could be deployed in humans readily 
since it is already in the anesthesiologist’s armamentarium. In 
isolated cases, the effect of specific ion channels (e.g., α5 sub-
unit-containing GABA
A
 receptor) has translated to produce 
something like delayed neurocognitive recovery, a diagnosis 
under the new perioperative neurocognitive disorder termi-
nology (see below under “Rodents [Mice and Rats]”).
Anesthetic exposures in these molecular approaches 
require special consideration, especially for the volatile anes-
thetics, as solubility is both limited and temperature-de-
pendent. For example, if equilibrated from a gas phase (e.g., 
bubbling), the concentrations achieved at room tempera-
ture (~22°C) could be three- to fivefold higher than those 
achieved at physiologic temperature (37°C). This is less of a 
problem if solutions are prepared by direct mixing of liquid 
anesthetic and buffers, although care must be taken to assure 
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the liquid is fully solubilized before use, and that the mixture 
is stored in the absence of a gas phase. For the injectable 
anesthetics, the solution should not include cosolvents or 
emulsifiers as in the case of the clinical propofol preparation, 
as these hydrophobic phases alter partitioning, making free 
drug concentrations unpredictably different than intended.
Nevertheless, like the strictly molecular approach, in situ 
molecular studies fail to mimic all the potentially contrib-
uting factors that occur during surgery, such as stress and 
inflammation.
Cell Culture Models
Cell culture models represent an enormous increment in com-
plexity as compared to molecular models of single proteins. A 
vast array of different cell types have been studied in the quest 
to understand the basis of anesthetic-induced perioperative 
neurocognitive disorder.10,28–40 Stable cell lines (e.g., Chinese 
hamster ovary, human embryonic kidney, neuroglioma), iso-
lated primary cells (e.g., hippocampal neurons grown in dis-
sociated cell cultures), stem cells (e.g., neural or mesenchymal 
progenitor cells, and human-induced pluripotent stem cells 
and derived neurons), and three-dimensional cell cultures (e.g., 
minibrain models) have been, or could be, exposed to a vari-
ety of different anesthetic drugs, at a wide range of concentra-
tions. Cell-based approaches have the advantage of ease, speed, 
and being highly mechanistic, but suffer from several limita-
tions as listed below. It is paramount for cell culture studies 
to verify the identity of cell lines and adhere to standards for 
authentication, handling, and reporting.
First, biologic variability is difficult to assess, as most 
such studies start with pooled cells, or immortal cell lines, 
in which all cells are essentially identical. At the same time, 
the ability to genetically transform cells is a distinct advan-
tage as genetically altered cells can help to dissect pathways 
that are important to some measurable adverse process (e.g., 
apoptosis, autophagy).
Second, anesthetic exposure conditions are uncertain, 
especially with the volatile compounds as the gas/liquid 
equilibration is slow and temperature-dependent as men-
tioned above (see Molecular section); media/gas partition-
ing is rarely measured.
Third, anesthetic concentrations that are required to 
induce “toxicity” in cell culture are often considerably 
higher than those that are administered clinically to intact 
animals or humans. This is a likely result of toxicity in ani-
mals being caused by physiologic disruption (hypoventila-
tion and hypotension, among others), which is challenging 
to mimic in isolated cells.
Fourth, for the injectable anesthetics like propofol, it is 
important to limit or eliminate cosolvents and emulsifiers 
(e.g., intralipid) that brain cells in intact animals would not 
be exposed to, and that complicate calculation of free drug, 
as mentioned above (see Molecular section).
Fifth, as noted above  (Molecular section), it is 
challenging to mimic surgery, although stimulation with 
damage-associated molecular patterns, cytokines, chemok-
ines or lipopolysaccharide has been reported in an attempt to 
reproduce some aspects of the inflammatory response,35,41,42 
and general cell stress can be induced through serum star-
vation or oxygen/glucose deprivation. Thus, while much 
has been learned from isolated cell studies, their ability to 
mimic the complex stress of surgery and anesthesia is lim-
ited, reducing translatability.
Finally, statistical approaches need to be considered care-
fully for cell culture studies. In a recent study of cell culture 
statistics methods (2011 to 2016), it was revealed that only 
22% of studies used replicates correctly.43 Researchers need 
to distinguish between biologic, experimental, and obser-
vational units, and realize that only the experimental unit 
refers to the sample size. In the case of biochemical studies 
using multiwell plates, wells of the same condition, on each 
day, are treated as subsamples and do not contribute to “n.” 
Thus, the individual wells should be averaged within the 
same condition on each day and the n is the number of 
days the separate experiments were performed. The bio-
logic “n” in primary culture will refer to the actual number 
of animals (if not pooled) from which the cell were isolated. 
Electrophysiologic studies often use a different standard, 
where each cell examined contributes to the “n” value. 
Most importantly, it is essential to state exactly what param-
eter the “n” value is referring to when reporting.
As examples, cell culture studies have shown that anes-
thetic drugs disrupt a number of different cytosolic signaling 
pathways, resulting in cell death,44,45 mitochondriopathy,46 
and/or the release of cytokines or other signaling molecules 
either during or after anesthetic exposure.35 Further, the 
enhancement of amyloidopathy and calcium dysregulation 
by anesthetics in cell models has been reported,8,45,47,48 each or 
all of which may contribute to postoperative cognitive dys-
function or perioperative neurocognitive disorder endpoints 
in intact animals. Cell-based models also allow the study of 
drugs that might oppose any adverse effect of anesthetics. For 
example, dantrolene can block the anesthetic-induced activa-
tion of calcium release from ryanodine receptor,49 and dex-
medetomidine prevents the overexpression of α5-containing 
GABA
A
 receptors on the neuronal surface.29
Brain Slice Models
Brain slice models maintain the integrity of at least some 
cell–cell communication and limited networks, which is 
another increment in complexity. Slice-based models also 
allow specific cell types located in discrete brain regions 
to be readily identified and tested. Anesthetic exposures 
have been shown to persistently disrupt functions of neu-
ronal networks such as the long-term potentiation of 
synapses,50–52 a cellular surrogate for memory and learn-
ing, which is possibly disrupted in postoperative cognitive 
dysfunction and perioperative neurocognitive disorder. In 
addition, slices can be obtained from genetically modified 
animals to define the role of specific proteins and signaling 
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pathways, and possibly offering insights into the heteroge-
neity of responses in humans.
Limitations of slice models are similar to the cell models 
in terms of anesthetic exposure, but in addition to an abil-
ity to measure function, strengths include an ability to assess 
biologic variability. Other limitations include reduced viabil-
ity of slices from aged animals,53 challenges in assessing neu-
rogenesis, and the fact that cell–cell connections, especially 
long-range ones that might be most influenced by anesthet-
ics, are invariably disrupted. Moreover, many cells are dam-
aged, are deprived of their normal circulation, and can be 
covertly ischemic. Thus, it is difficult to know if responses to 
an intervention can be considered physiologic. Nevertheless, 
unlike the cell culture models, robust and relevant functions 
can be measured at least briefly; but evaluation of the effects 
of age, surgery and inflammation remain challenging.
animal Models of postoperative cognitive 
Dysfunction and perioperative Neurocognitive 
Disorder
Many animal models that range from worms to nonhuman 
primates have been used to study anesthetic neurotoxicity, 
but the most ubiquitous, tractable, and relevant have been 
mammalian models, primarily rats and mice. It is important 
here to make the distinction between studies at the two 
extremes of age. Considerable investigation of the effect 
of anesthetics on the developing animal brain has been 
published over the past decade, and this body of work is 
reviewed in detail elsewhere.54 When referring to periop-
erative neurocognitive disorder and postoperative cognitive 
dysfunction, we focus on the effect of anesthesia and surgery 
on the aging animal brain specifically. No studies of periop-
erative neurocognitive disorder and postoperative cognitive 
dysfunction in nonhuman primates have been reported, and 
this model presents considerable disadvantages in terms of 
cost and life span, so will not be further discussed.
Caenorhabditis elegans (Nematode)
This small (1 mm in length) free-living nematode has been 
extensively studied for decades from a genetic standpoint. 
Specifically, this model has been used primarily to define the 
genetic determinants of general anesthetic drug sensitivity.55 
The advantages of this model include a very short life cycle, 
ease of husbandry, being an invertebrate (no Institutional 
Animal Care and Use Committee concerns), clear and 
consistent behavior, completely sequenced genome, trans-
parency, and a structurally understood nervous system. It is 
also sensitive to all general anesthetics, although about five- 
to tenfold less sensitive than mammals.56,57 Disadvantages 
include small size, making electrophysiology difficult, and a 
very primitive nervous system containing only 302 neurons. 
Whether worms can truly learn and remember is contro-
versial, limiting relevant outcome measurements. Relevance 
and translatability are the primary concerns, although many 
biologic features first identified in this nematode have been 
subsequently validated in the mammal. Postoperative cog-
nitive dysfunction and perioperative neurocognitive dis-
order studies are very limited. Both forward and reverse 
genetic designs have been used to study a wide variety of 
phenotypes, including aging. Although the worm has been 
used to define pathways and mechanisms for specific pro-
teinopathies, such as Alzheimer disease,58 it has not received 
much attention in the postoperative cognitive dysfunction 
and perioperative neurocognitive disorder domain, proba-
bly because of the concerns regarding translation.
Drosophila melanogaster (Fruit Fly)
While flies are not much larger than worms, their nervous 
systems are considerably more complex. The fruit fly has been 
studied extensively, although the studies are devoted largely 
to the genotype and phenotype relationship. Much work has 
been conducted in the neurodegeneration pathways,59 but 
again, little in the postoperative cognitive dysfunction and 
perioperative neurocognitive disorder domain. In contrast, it 
has been a popular organism to understand the genetic deter-
minants of general anesthetic sensitivity,60,61 and more recently 
it is being used to understand polytrauma and sepsis.62,63 The 
advantages are its easy husbandry, fully understood genetics, 
large numbers of readily available variants, short generation 
and life span, and lack of regulatory oversight. While the 
administration of volatile anesthetics is straightforward, the 
administration of injectable drugs is not. Similar to studies 
of worms, it is difficult to measure anesthetic concentrations 
in vivo.64 Nevertheless, because of the previous and ongoing 
work in neurodegeneration, sepsis, and anesthesia, it seems that 
an opportunity to study postoperative cognitive dysfunction 
and perioperative neurocognitive disorder exists in the fly.
Danio rerio (Zebrafish)
Similar to the nematode and fruit fly, the zebrafish is 
extremely well understood from a genetic and developmen-
tal standpoint. Unfortunately, this versatile experimental 
model has received little or no attention in the postopera-
tive cognitive dysfunction and perioperative neurocognitive 
disorder domain, or for that matter by the entire field of 
anesthesiology. An important advantage of the zebrafish is 
that, as a vertebrate, it is phylogenetically closer to mammals 
than the fruit fly or worm. However, as alluded to above in 
the Nematode and Fruit Fly sections, this requires that pro-
tocols involving fish be approved by Institutional Animal 
Care and Use Committees. Like flies and worms, the fish is 
well understood genetically, and many genetic variants are 
available. Anesthetic administration is more straightforward, 
as any drug that can be solubilized in pond water will be 
rapidly absorbed via diffusion through the skin or across 
the gills, and can be used for high-throughput screening.65 
There may be little advantage for the study of aging, or 
age-related processes like neurodegeneration, since their life 
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span is similar to the mouse, so the examination of aged 
fish becomes difficult. Nevertheless, models of Alzheimer 
disease–like neurodegeneration have been reported for both 
adult and larval zebrafish.66 Also, behavioral measurements 
in the larvae are limited to stereotypical responses to various 
forms of stimulation, although learning and memory can be 
studied in the adult fish. To date, no postoperative cogni-
tive dysfunction and perioperative neurocognitive disorder 
work has been reported using the zebrafish, but it should 
be useful for genetic dissection of the pathways involved. 
Otherwise, advantages over the mouse appear to be small.
Rodents (Mice and Rats)
The mouse has been the mainstay of postoperative cogni-
tive dysfunction and perioperative neurocognitive disor-
der research to date, because of its size, cost, and ability to 
modify its genome. Rats have been used in some studies. 
Initial studies examined the effect of anesthetics on memory 
and learning, typically using some form of a maze task or 
fear-conditioning assays. Almost invariably, it was found that 
the state of anesthesia, produced largely by inhalational drugs, 
produced decrements in learning and memory that could be 
detected a few days or a week after the exposure.9,67 In some 
cases, these decrements were associated with changes in his-
topathology or biomarkers consistent with neurodegenera-
tion.68,69 The largely wild-type (e.g., C57BL/6) mice used in 
these studies were of different ages, and the exposures were 
very different, making comparisons difficult.
In attempts to make the models more representative of 
patient populations with postoperative cognitive dysfunc-
tion and perioperative neurocognitive disorder, researchers 
included other stresses or vulnerabilities. For example, recent 
studies have included aged rodents, typically 18 to 24 months 
of age. In older animals, postanesthesia behavioral decrements 
tend to be larger and more durable.9,70,71 Moreover, since 
many patients come to surgery with preexisting cognitive 
impairments, and since wild-type rodents tend not to suffer 
from anything resembling Alzheimer disease, researchers have 
begun to repeat their studies with transgenic animals that 
include human Alzheimer disease–related genes. Most pop-
ular have been genes in the amyloid β pathway that enhance 
production and therefore increase brain levels of amyloid β 
(e.g., Tg2576, APP/PS1). This strategy, when coupled with 
age, has revealed further decrements in learning and memory, 
although not necessarily representing neurodegeneration. 
Inhalational anesthetic exposure accelerated features of the 
histopathology, but not the learning and memory deficits.67,72 
Other transgenic animals that recapitulate tauopathy73 or 
include both amyloidopathy and tauopathy (3xTgAD, hTau 
mice), in order to better recapitulate human disease, have even 
larger deficits.74 In these animals, inhalational anesthetics pro-
duced no effect on behavior when young,75 but a transient 
decrement in learning and memory when aged.14 Isolated 
tauopathy models have also been studied, which show ampli-
fied consequences of being exposed to an anesthetic.20,73
In addition to the disease-pathway mechanisms, there are 
reports of canonical anesthetic mechanisms that produce 
delayed neurocognitive effects. For example, a portion of 
the hypnotic, amnestic, and immobilizing actions of many 
general anesthetics is thought to occur via enhancement or 
activation of GABA
A
 receptor activity.76,77 In receptors that 
contain the α5 subunit, anesthetics enhance expression in 
the neuronal membranes, a location where they become 
persistently active. This has been shown in animals to result 
in transient somnolence, amnesia, and cognitive impair-
ment, similar to human delayed neurocognitive recovery.78 
Specific antagonists of the α5 GABA
A
 receptor have been 
reported to improve animal behavior after anesthetic expo-
sure.29,78 It is not yet clear to what degree such a mechanism 
contributes to human perioperative neurocognitive disor-
der and postoperative cognitive dysfunction.
A very large advantage of the rodent over the other 
animal species mentioned above is the ability to include 
surgery, clearly a central part of the perioperative experi-
ence. Thus, most studies that have included surgery along 
with the anesthetic14,79–82 have found a consistent increment 
in both the histopathology and biochemical evidence of 
neuroinflammation, and a greater decrement in the behav-
ior. When age, a genetic vulnerability, a comorbidity, and 
surgery were all combined in the study design, the decre-
ments in behavior became much more durable (more than 
3 months).14 Interestingly, despite the anesthetic having lit-
tle detectable effect on its own, it appears that some anes-
thetics can modulate the result of having either a genetic 
vulnerability83 or surgery.81 The concept that best explains 
the rodent data to date is a modified “double-hit” model. In 
other words, in the presence of preexisting vulnerabilities 
(e.g., age, genetic, and comorbidities), the large multifac-
torial stress of the surgery amplifies any ongoing central 
nervous system inflammation or injury, a process potentially 
modulated by other drugs like anesthetics.
Evidence suggests that neuroinflammation after surgery 
plays a key role in postoperative cognitive dysfunction and 
perioperative neurocognitive disorder.84,85 The preexisting 
vulnerabilities mentioned above are thought to increase 
blood brain barrier permeability,86 and allow the periph-
eral innate immune molecules, generated by surgical tis-
sue damage, to enter the central nervous system to further 
enhance neuroinflammation and injury. Moreover, mice 
that lack genes to mount significant neuroinflammation 
did not develop postoperative cognitive dysfunction after 
anesthesia and surgery.87,88 Even in the absence of surgery, 
stimulation of the innate immune response by lipopolysac-
charide, or inducing sepsis, produces transient decrements 
in behavioral assays, reminiscent of delayed neurocogni-
tive recovery, or “sickness behavior.”89,90 Blockage of either 
tumor necrosis factor α or interleukin 6 using antibodies 
effectively reduced rodent postoperative cognitive dys-
function, but also delayed wound healing.79,82 More con-
ventional antiinflammatory drugs (dexamethasone  and 
Copyright © 2019, the American Society of Anesthesiologists, Inc. Unauthorized reproduction of this article is prohibited.Downloaded from anesthesiology.pubs.asahq.org by Roderic G. Eckenhoff on 09/19/2019
Special article
6 Anesthesiology 2019; XXX:00–00 Eckenhoff et al.
cyclooxygenase-2 inhibitors) given before, during, or after 
the procedure have yielded variable results,91–95 a result that 
has shifted attention to innate processes that actively turn 
off or resolve inflammation. Initial studies of mice with the 
tibial fracture model show promising results with proreso-
lution strategies, such as resolvin-D1 and maresin-1,96,97 as 
well as bioelectronic approaches, such as electrical stimula-
tion of the vagus nerve.98
The impact of anesthesia and surgery on patients with 
other forms of neurodegeneration, such as Parkinson 
disease or prion diseases, or on pre-existing cerebrovas-
cular disease, have not been reported, despite these disor-
ders being fairly common in aged surgical populations. 
Similarly, traumatic brain injury is thought to enhance 
vulnerability to Alzheimer disease and Parkinson disease. 
The effect of anesthesia and surgery on perioperative 
neurocognitive disorder and postoperative cognitive dys-
function in humans or animals with a history of even mild 
traumatic brain injury has not been reported. Moreover, 
an association between depression and educational and 
socioeconomic status with cognitive trajectories has been 
reported in human forms of neurodegeneration, another 
area intrinsically difficult to model in the preclinical 
domain, especially with rodents. The beneficial potential 
for some forms of nonpharmacologic approaches is sug-
gested by evidence showing that environmental enrich-
ment slows cognitive decline in a murine Alzheimer 
disease model,99,100 as well as postoperative cognitive dys-
function in rodents.101,102 Growing evidence also impli-
cates the gut microbiome in several neuroinflammatory 
models, and its contribution in perioperative neurocogni-
tive disorder is just beginning to be explored.103
Suggestions for rodent perioperative 
Neurocognitive Disorder and postoperative 
cognitive Dysfunction research
The hundreds of rodent studies of perioperative neurocog-
nitive disorder and postoperative cognitive dysfunction that 
appear every year in the literature are very heterogeneous 
in both design and results; translation has been limited. It 
is likely that at least a portion of the variability could be 
reduced by adherence to reporting guidelines, such as that 
promulgated for animal study of stroke in 2010 (e.g., Animal 
Research: Reporting of In Vivo Experiments [ARRIVE]).104 
It should be noted that even 4 to 6 yr after publication of 
the Animal Research: Reporting of In Vivo Experiments 
guidelines, very few relevant preclinical studies published in 
the anesthesiology literature have adhered to or have even 
cited them.105 In addition to those guidelines for report-
ing, we would also like to suggest that investigators con-
sider the following guidelines when designing their studies. 
These guidelines touch on terminology, animal character, 
exposure control and monitoring, procedures, and finally, 
statistical considerations.
Terminology
The term postoperative cognitive dysfunction has been 
used in the clinical literature to refer to any postoperative 
cognitive dysfunction, usually in a research context, and 
regardless of magnitude, timing or duration. Unfortunately, 
the same has been true in the preclinical literature. As men-
tioned in the introduction, a recent set of recommenda-
tions for a new clinical nomenclature has been published 
in order to recognize the many inadequacies of postoper-
ative cognitive dysfunction.7 These recommendations were 
not intended for preclinical research, and cannot reliably be 
mapped onto, for example, performance on the fear con-
ditioning assay, or water maze. Nevertheless, we encourage 
researchers to make an attempt, in the discussion or inter-
pretation of their results, to indicate roughly where their 
study design fits. For example, many rodent studies have 
found minor but significant performance deficits out to a 
week or two postoperatively, with full apparent recovery 
thereafter. This might parenthetically be termed delayed 
neurocognitive recovery, even though the required “cog-
nitive concern” cannot be voiced. In another study where 
the deficits appeared to be persistent even to 3 months 
postoperatively, this might be “neurocognitive disorder,” 
again with the same caveat regarding the cognitive concern. 
Also, given that the animals could maintain their weight 
and other “activities of daily living” (a pretty low bar in the 
rodent), this would probably be closest to “mild” neurocog-
nitive disorder. Ultimately, however, researchers simply need 
to be precise about what they did and why when reporting.
Animal Age, Sex, and Environment
Perioperative neurocognitive disorder and postoperative 
cognitive dysfunction is a syndrome of the elderly, and 
it is clear that the aged brain reacts differently to stresses 
than the young.106,107 Thus, studies of perioperative neuro-
cognitive disorder and postoperative cognitive dysfunction 
mechanisms and influences should include animals aged to 
at least 70 to 80% of their expected life span. It is recog-
nized that this increases the cost and time of studies, but 
the tradeoff of potentially improved translation more than 
justifies the cost. Sex is an important biologic variable that 
must be considered in perioperative neurocognitive dis-
order and postoperative cognitive dysfunction research. 
Delirium and cognitive impairment are reported in both 
male and female patients, and thus, strong scientific justifi-
cation should accompany the reporting of only a single sex. 
In addition to age, preexisting cognitive decline is a major 
risk factor for perioperative neurocognitive disorder and 
postoperative cognitive dysfunction, so modification to a 
rodent’s genome or environment (drugs) that produce these 
cognitive impairments, while not essential, may be import-
ant to include when a researcher is establishing relevance 
for the human condition, as well as searching for mech-
anisms. Finally, a preclinical focus on persistent cognitive 
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impairment after surgery merits greater attention, as it is 
the most controversial aspect of perioperative neurocogni-
tive disorder and postoperative cognitive dysfunction in the 
clinical literature.
Anesthetic Exposures
Most general anesthetics depress ventilation, body tempera-
ture, cardiac output, and blood pressure, any one of which 
can also have an effect on the brain in addition to any direct 
influences of the drug. While these physiologic perturba-
tions are monitored and controlled in the human (or other 
large animal species), they are often not even monitored, 
let alone controlled, in typical rodent models. We suggest 
that, at a minimum, temperature and oxygen saturation be 
monitored; optimally, blood pressure and heart rate should 
be included. Miniaturized equipment for this purpose is 
now commercially available for rodents. The inhaled oxy-
gen should be enriched to avoid hypoxemia, but probably 
not beyond 50% to avoid atelectasis and oxygen toxicity. 
While mechanical ventilation might be desirable to elimi-
nate hypercarbia, and the accompanying respiratory acido-
sis, this can be prohibitively difficult in the mouse—less so 
in the rat. Measurement of arterial blood gases would be 
ideal, but the approach and blood volumes needed typi-
cally preclude survival beyond collection, and may be mod-
el-specific depending on length of anesthesia exposure or 
surgery duration. Most investigators who actually measure 
blood gases do so in sentinel animals euthanized solely for 
this purpose at different points in the exposure. Perhaps 
because it sometimes requires surgery, electroencephalo-
graphic monitoring of aged animals undergoing anesthesia 
has not been reported in postoperative cognitive dysfunc-
tion and perioperative neurocognitive disorder studies, 
but might be considered since the anesthetic sensitivity of 
genetically altered animals is rarely determined before using 
them in such studies. In addition, electroencephalographic 
monitoring would provide evidence of physiologic change 
(e.g., hypotension and decreased cerebral perfusion) that 
could confound the results.
Mortality is not uncommon in rodent anesthetic stud-
ies, especially in aged and genetically modified animals, and 
in general reflects pronounced physiologic disruption that 
can be presumed to have existed even in the animals that 
survive. Thus, it is difficult to rationalize that such a study 
is examining the effect of the anesthetic per se, rather than 
marked physiologic trespass. Mortality due to the anesthetic 
is exceedingly rare in human anesthesia practice. Animal 
Research: Reporting of In Vivo Experiments guidelines 
should be followed to report mortality as well as any other 
exclusions to the experimental groups. Finally, it is not clear 
how long an animal exposure to anesthesia is “relevant.” 
This should not be based on life span alone; it should be 
evaluated in the context of each experimental model based 
on previous literature, physiologic monitoring, and transla-
tional relevance.
Surgical Procedure
Reported surgical procedures in rodents have varied, and 
have included simple skin incision and vascular exposure, 
splenectomy,  cecectomy and appendectomy, partial hepa-
tectomy, and tibial fracture.108 Other models exist but have 
not been explored for perioperative neurocognitive disor-
der, such as cardiopulmonary bypass.109 All have merit, as 
postoperative cognitive dysfunction in humans has been 
reported after each, albeit at a different incidence and mag-
nitude. Splenectomy may not be the best choice as it is 
uncommon surgery in older adults and itself modulates the 
innate immune response. As in human surgery, antibiotics 
and analgesics are used in the rodent, and while under-
studied, these drug classes may have a significant impact 
on perioperative neurocognitive disorder and postoperative 
cognitive dysfunction.110
Behavioral Assays
The earliest form of perioperative neurocognitive disor-
der to occur in the human after anesthesia and surgery is 
postoperative delirium, which, despite considerable effort, 
has only been partially validated in the rodent.111,112 For 
example, fluctuating level of attention has been reported, 
but detecting disordered thinking and hallucinations in the 
rodent, and distinguishing them from fear, anxiety, and pain, 
would be necessarily arbitrary. On the contrary, there are 
a large number of well-validated assays of rodent learning 
and memory, as well as motor and coordination ability. 
Similarly, there are a large number of ways these assays are 
administered, in some cases with training beforehand, and 
others without a training phase at all. There are excellent 
reviews on the subject of animal behavior testing in aged 
and transgenic animals, so we will not go into detail here, 
but with respect to perioperative neurocognitive disorder 
and postoperative cognitive dysfunction, we can offer the 
following suggestions. Since human perioperative neuro-
cognitive disorder and postoperative cognitive dysfunction 
signs and symptoms occur in multiple cognitive domains, 
more than a single rodent behavioral assay should be used. It 
is not uncommon to find no effect in one assay and signif-
icant effects in another, but the results of all assays, includ-
ing those with negative findings, should be reported. Since 
most assays are reliant on some level of motor activity, and 
some surgical procedures may result in motor impairment 
or pain that will impact assay results and interpretation, it 
is useful to include independent motor ability assays, such 
as the rotarod. Also, transgenic and aged animals cannot be 
assumed to have entirely intact sensory systems (olfaction 
and vision, among others), on which many behavioral assays 
are critically dependent; baseline values and control groups 
are necessary. Evidence suggests that environment, includ-
ing the researchers themselves,113 influences rodent behav-
ior, suggesting that these variables be carefully controlled. 
Finally, because any measure of behavior includes a degree 
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of subjectivity, variability will be high, indicating that a large 
number of animals will be required to give confidence in 
the results. For example, it is unlikely that group sizes of 
five or six animals will be sufficient to detect anything but 
a type I error.
Statistical Methods
Statistical methods vary greatly depending on the experi-
mental model and design. Preclinical studies often have the 
advantage of low biologic variability, which reduces the 
numbers of cells or animals necessary to show significant 
effect sizes. However, this advantage is also a weakness, as a 
system with low biologic variability does not reflect typical 
human surgical populations, partially explaining the well-
known translational failure.
Sample Size. Statistical methods should be rigorously 
addressed during the experimental design, and not after data 
collection. The first step is to define primary and secondary 
endpoints in behavioral studies, as occurs in clinical trials. 
Next is a power analysis, which is typically based on pilot 
data and performed prospectively. This allows an estimate 
of the effect size, which can be used to calculate the “n” 
required to achieve statistical significance.114,115 Lacking 
pilot data, the effect size can often be estimated from the 
literature, or at least from what a “clinically significant” effect 
size might be. For example, most would consider a 10% 
decrease in cognitive ability after surgery to be clinically 
very important, but this would be considered a very small 
effect size in an animal, and therefore require a large “n” to 
reveal it significantly. Further, estimating effect sizes from 
the literature could be misleading as it might be merely 
propagating errors. We recommend that a biostatistician be 
integrated into the design phase of these preclinical studies 
in order to power the study appropriately.
Statistical Approach. The actual test will depend on the 
experimental design. Student’s t test for predetermined 
and independent pairs of samples (e.g., a primary outcome 
in treated and control groups) as well as ANOVA (when 
more than two groups are present: two treatment groups 
as compared to a control) are acceptable statistical methods 
used in preclinical studies, but only when the data are 
normally distributed. When not normally distributed, which 
is often the case, nonparametric tests must be considered 
to avoid misleading results. When multiple independent 
tests are planned, with no a priori focus, such as is common 
in enzyme-linked immunosorbent assay (ELISA) arrays, 
corrections for multiple testing must be used.115 Similarly, 
if multiple time points or treatments are planned, ANOVA 
followed by a suitable post hoc test is required to correct for 
these multiple comparisons. In addition to null hypothesis 
testing, it is essential to consider effect sizes and their 
95% CI in order to gauge translational relevance. Finally, 
as outlined in the Animal Research: Reporting of In Vivo 
Experiments guidelines, all data, negative and positive, as 
well as statistical methods should be reported, indicating 
any outliers and deaths that have been excluded and the 
reasons for exclusion. While it is understood that a negative 
result reporting bias exists, such reporting is vital to avoid 
needless repetition and improve translatability.
Rigor and Reproducibility. Funding agencies internationally 
are concerned about low reproducibility and translatability, 
which is in large part due to underpowered sample sizes, as 
well as experimental designs that do not include blinding, 
randomization, replication, positive and negative controls, 
and biologic differences.116,117 Further, critical biologic 
variables like age, sex, and comorbidities are often not 
considered, and are often difficult to include in preclinical 
studies. Novel approaches to experimental design should be 
considered,118,119 and one should work with a biostatistician 
from the beginning. It bears emphasizing that once 
published, poorly designed studies become part of the 
literature and difficult to distinguish from well-designed 
and reported ones. Ultimately this harms all researchers 
through loss of time and scarce research dollars.
Conclusions
The preclinical examination of perioperative neurocog-
nitive disorder and postoperative cognitive dysfunction 
has revealed much in the way of mechanistic insight into 
cognitive impairment after anesthesia and surgery, and sev-
eral compelling hypotheses regarding neuroinflammation, 
inflammation resolution, and adverse anesthetic effects 
have emerged. Barriers to progress exist, many of which 
lie in the area of experimental design, consistency, report-
ing, and terminology. Other barriers include the exper-
imental and animal models themselves. In vitro, cell and 
slice studies suffer from an incomplete ability to model the 
perioperative experience, now especially important given 
the growing appreciation for the impact of the surgical 
procedure. Barriers also exist in the modeling of human 
vulnerabilities in animal models, and an imprecise ability 
to evaluate cognitive domains affected, such as executive 
function, attention, and disordered thinking. These exper-
imental shortfalls have conspired to reduce translation of 
research results to humans.
Nevertheless, the various preclinical models will continue 
to be essential to address focused questions, and collectively 
the answers from these various models and approaches will be 
highly complementary. For example, what are the upstream 
targets that surgery and/or anesthetics activate to produce 
the cascades resulting in delirium and cognitive decline? Can 
targeting these pathways mitigate injury? What is the impact 
of preexisting neuronal vulnerabilities other than Alzheimer 
disease, such as Parkinson disease and traumatic brain injury? 
Very little has been reported regarding the effects of many 
other aspects of the perioperative period such as different 
sedatives, analgesic drugs, antibiotics, changes in the gut 
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microbiome, sleep disruption, and immobility. Also needed 
is a greater focus on specific pathways within the innate 
immune response, such as immune cell activation, adher-
ence, and migration, or the importance of vagal traffic. Also 
still in its infancy is the focus on inflammatory resolution, 
an area that shows promise for both prevention and, poten-
tially, treatment of perioperative neurocognitive disorder and 
postoperative cognitive dysfunction. Finally, improved animal 
assays for delirium, socialization, and problem-solving need 
to be adopted, as well as models of depression, social defeat, 
and socioeconomic status. All of these psychosocial factors 
deserve special attention as research has demonstrated that 
environmental enrichment has overcome the cognitive defi-
cits due to a variety of stresses. These and many other knowl-
edge gaps (detailed in table 1) cannot be easily addressed in 
clinical studies; much impactful preclinical work remains.
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